

Research Article

See Perspective on p. 957

Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate

L. Allyson Checkley¹, Okkyung Rho¹, Tricia Moore², Steve Hursting², and John DiGiovanni^{1,2}

Abstract

Aberrant activation of phosphoinositide-3-kinase (PI3K)/Akt signaling has been implicated in the development and progression of multiple human cancers. During the process of skin tumor promotion induced by treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), activation of epidermal Akt occurs as well as several downstream effectors of Akt, including the activation of mTORC1. Rapamycin, an established mTORC1 inhibitor, was used to further explore the role of mTORC1 signaling in epithelial carcinogenesis, specifically during the tumor promotion stage. Rapamycin blocked TPA-induced activation of mTORC1 as well as several downstream targets. In addition, TPA-induced epidermal hyperproliferation and hyperplasia were inhibited in a dose-dependent manner with topical rapamycin treatments. Immunohistochemical analyses of the skin from mice in this multiple treatment experiment revealed that rapamycin also significantly decreased the number of infiltrating macrophages, T cells, neutrophils, and mast cells seen in the dermis following TPA treatment. Using a two-stage skin carcinogenesis protocol with 7,12-dimethylbenz(a)anthracene (DMBA) as initiator and TPA as the promoter, rapamycin (5–200 nmol per mouse given topically 30 minutes prior to TPA) exerted a powerful antipromoting effect, reducing both tumor incidence and tumor multiplicity. Moreover, topical application of rapamycin to existing papillomas induced regression and/or inhibited further growth. Overall, the data indicate that rapamycin is a potent inhibitor of skin tumor promotion and suggest that signaling through mTORC1 contributes significantly to the process of skin tumor promotion. The data also suggest that blocking this pathway either alone or in combination with other agents targeting additional pathways may be an effective strategy for prevention of epithelial carcinogenesis. *Cancer Prev Res*; 4(7); 1011–20. ©2011 AACR.

Introduction

The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway is one of the most commonly altered pathways found in human tumors (1, 2). Although there is an established connection between deregulated Akt signaling and cancer development and progression, the downstream effectors mediating tumorigenesis have not been fully defined. Recent evidence has indicated that the mammalian Target of Rapamycin (mTOR), a target of Akt, and subsequent downstream signaling may play a critical role in mediating at least some of the effects of aberrant Akt signaling during tumorigenesis (3–5). mTOR is a serine/threonine protein kinase that regulates cellular growth and proliferation by controlling

protein synthesis (6). It is composed of 2 complexes: mTORC1, the rapamycin-sensitive complex in which mTOR associates with raptor and mLST8; and mTORC2, the rapamycin-insensitive complex in which mTOR associates with rictor, mLST8, and mSIN1 (7). mTORC1 phosphorylates downstream targets p70S6K and S6 ribosomal protein and also phosphorylates and inactivates the translational repressor 4E-BP1 to regulate protein synthesis (8). mTORC2 is activated by receptor tyrosine kinases via an unknown mechanism and phosphorylates Akt at serine 473 (9).

Because of its central role in cellular growth and proliferation, mTOR is an attractive target for both treatment and prevention of cancer (10, 11). Rapamycin, an established mTORC1 inhibitor, has been shown to suppress tumorigenesis in a variety of xenograft models (12–14). In addition, rapamycin has been found to impair the growth of primary skin carcinomas induced by chronic exposure to UV (15). Rapamycin has also been shown to exhibit significant tumor-suppressing effects on existing squamous cell carcinomas (SCCs) of the skin induced by the two-stage chemical carcinogenesis protocol (16) as well as display chemopreventive activity against carcinogen-induced lung cancer in A/J mice (17, 18). Rapamycin has also been evaluated in several transgenic models where it inhibited tumor

Authors' Affiliations: ¹Division of Pharmacology and Toxicology and ²Department of Nutritional Science, The University of Texas at Austin, Austin, Texas

Corresponding Author: John DiGiovanni, Dell Pediatric Research Institute, The University of Texas at Austin, 1400 Barbara Jordan Blvd. Austin, TX 78723. Phone: 512-495-4726; Fax: 512-495-4945. E-mail: jdigiiovanni@mail.utexas.edu

doi: 10.1158/1940-6207.CAPR-10-0375

©2011 American Association for Cancer Research.

progression. For example, in a mouse model for head and neck SCC (based on *K-ras*^{G12D} expression and p53 loss in oral epithelium), rapamycin inhibited tumor progression and increased survival (19). In addition, rapamycin also decreased tumor growth and angiogenesis in a mouse model of erbB2-dependent human breast cancer (20) and inhibited tumor growth in a mouse model of prostate cancer (21).

During epithelial carcinogenesis in mouse skin, sustained activation of Akt has been found as tumors progress from papillomas to SCCs (22). Treatment of mouse skin with diverse tumor promoting stimuli leads to activation of Akt in epidermis as well as increased phosphorylation of several downstream effectors of Akt including mTOR, GSK3 β , and BAD (23). These biochemical changes are sustained during the early stages of skin tumor promotion (23, 24). Collectively, these data suggested a possible role for one or more Akt downstream pathways in skin tumor promotion. In addition, mice overexpressing wild-type Akt1 (Akt^{wt}) or a constitutively active form of Akt1 (Akt^{myr}) in the epidermis exhibited dramatically enhanced susceptibility to two-stage skin carcinogenesis (24). After treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA), Akt^{wt} transgenic mice displayed prolonged activation of Akt as well as several downstream targets including mTORC1 as compared with nontransgenic mice. These data also suggested that the enhanced susceptibility to skin tumor promotion in Akt transgenic mice may be due, in part, to elevated mTORC1 signaling.

In the present study, we have assessed the ability of rapamycin to inhibit skin tumor promotion by TPA. Topical administration of rapamycin dramatically inhibited skin tumor promotion by TPA in a dose-dependent manner. In addition, rapamycin induced regression (and/or inhibited growth) of pre-existing papillomas. Topical treatment with rapamycin effectively blocked TPA-induced epidermal hyperproliferation as well as dermal inflammation. Biochemical studies showed that rapamycin reduced TPA-induced epidermal signaling through the mTORC1 pathway. Rapamycin appeared to exert its potent inhibitory effects on skin tumor promotion by TPA through inhibition of mTORC1 signaling in keratinocytes leading to inhibition of epidermal proliferation. In addition, rapamycin inhibited TPA-induced inflammation that may also contribute to its potent antipromoting effects. Together, these data show that rapamycin is a highly potent inhibitor of skin tumor promotion and support the hypothesis that signaling through mTORC1 contributes significantly to the process of skin tumorigenesis and tumor promotion. Blocking this pathway may be an effective strategy for prevention of epithelial carcinogenesis either alone or in combination with other agents that target additional signaling pathways activated during the process of tumor promotion.

Materials and Methods

Chemicals and reagents

7,12-dimethylbenz(*a*)anthracene (DMBA), bromodeoxyuridine (BrdU), proteinase inhibitor cocktails, phosphatase inhibitor cocktails, anti-actin as well as anti-mouse and anti-rabbit secondary antibodies were purchased from Sigma Chemicals Co. TPA was purchased from Alexis Biochemicals. Rapamycin was purchased from LC Laboratories. Antibodies against phosphorylated mTOR (Ser²⁴⁴⁸), mTOR total, phosphorylated Akt (Thr³⁰⁸ or Ser⁴⁷³), Akt total, phosphorylated p70S6K (Thr³⁸⁹), total p70S6K, phosphorylated S6 ribosomal protein (Ser^{240/244}), and phosphorylated 4E-BP1 (Thr^{37/46} or Ser⁶⁵) were purchased from Cell Signaling Technology, Inc. Chemiluminescence detection kits were purchased from Pierce.

tase inhibitor cocktails, anti-actin as well as anti-mouse and anti-rabbit secondary antibodies were purchased from Sigma Chemicals Co. TPA was purchased from Alexis Biochemicals. Rapamycin was purchased from LC Laboratories. Antibodies against phosphorylated mTOR (Ser²⁴⁴⁸), mTOR total, phosphorylated Akt (Thr³⁰⁸ or Ser⁴⁷³), Akt total, phosphorylated p70S6K (Thr³⁸⁹), total p70S6K, phosphorylated S6 ribosomal protein (Ser^{240/244}), and phosphorylated 4E-BP1 (Thr^{37/46} or Ser⁶⁵) were purchased from Cell Signaling Technology, Inc. Chemiluminescence detection kits were purchased from Pierce.

Animals and treatments

Female FVB/N mice in the resting stage of the hair cycle (7–9 weeks of age) were obtained from the National Cancer Institute and group housed for the duration of the study in all experiments.

Biochemical analyses. For multiple treatment experiment, groups of 6 mice each were dorsally shaved and treated twice weekly for 2 weeks (i.e., 4 treatments total) with acetone vehicle (0.2 mL), 6.8 nmol of TPA, 1,000 nmol of rapamycin, or rapamycin (5–1,000 nmol) in 0.2 mL acetone 30 minutes prior to 6.8 nmol of TPA. Mice were sacrificed 6 hours after final treatment and again pooled, epidermal protein lysates were prepared.

Histologic analyses. For the evaluation of epidermal hyperplasia, labeling index (LI), and immune cell infiltration, the dorsal skin of mice (3 mice per group) was shaved, and then topically treated with 0.2 mL of acetone (vehicle), 6.8 nmol of TPA, 200 nmol of rapamycin, or rapamycin (5–200 nmol) 30 minutes prior to TPA. Mice were treated twice weekly for 2 weeks and sacrificed 48 hours after the last treatment. Mice received an intraperitoneal injection of BrdU (100 μ g/g body weight) in 0.9% NaCl 30 minutes prior to sacrifice. Dorsal skin samples were fixed in formalin, embedded in paraffin, and then sectioned. Sections were cut and stained with hematoxylin and eosin (H&E), anti-BrdU, LY6G, S100A9, or CD3. Epidermal thickness and LI were determined as described previously (25). Immune cell infiltration was determined by the number of positive-stained cells per 200 μ m² field (24 fields per slide).

Two-stage skin carcinogenesis. Groups of 20 mice each were used for the two-stage skin carcinogenesis studies. The backs of mice were shaved 48 hours prior to initiation. All mice received a topical application of 25 nmol of DMBA in 0.2 mL acetone to the shaved dorsal skin. Two weeks after initiation, mice were treated topically with various doses of rapamycin (5–200 nmol) in 0.2 mL acetone or vehicle (acetone) followed 30 minutes later by promotion with 6.8 nmol TPA in 0.2 mL acetone twice weekly until tumor multiplicity reached a plateau (25 weeks). All mice were weighed weekly during the course of the 25-week promotion period. Tumor incidence (percentage of mice with papillomas) and tumor multiplicity (average number of papillomas per mouse) were also recorded weekly for the duration of the study.

Preparation of epidermal lysates

After sacrifice, a depilatory agent was applied to the dorsal skin for 30 seconds and then removed under cold running water. The skin was then excised and the epidermal layer was removed by scraping with a razor blade into radioimmunoprecipitation assay (RIPA) lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L sodium orthovanadate, 1% NP-40, phosphatase inhibitor cocktail 1 and 2, and proteinase inhibitor cocktail). The tissue was then homogenized using an 18-gauge needle. Epidermal scrapings from 6 mice were pooled to generate epidermal protein lysates for Western blotting. Lysates were centrifuged at 14,000 rpm for 15 minutes and either used immediately for Western blot analysis or snap frozen in liquid nitrogen and stored at -80°C until used.

Western blot analyses

For analysis of Akt/mTOR activation, 50 μg of epidermal protein lysate was electrophoresed in 4% to 15% SDS-PAGE gels and then transferred onto nitrocellulose membrane (BioRad). The membranes were blocked for 1 hour in 5% bovine serum albumin (BSA) in TBS with 1% Tween (TTBS) and incubated overnight at 4°C with designated antibodies. After incubation, the membranes were washed 3 times for 10 minutes each in TTBS prior to incubation with secondary antibodies for 1 hour at room temperature. After additional washes (3 washes, 10 minutes each) to remove unbound secondary antibody, protein bands were then visualized using chemiluminescence detection (Pierce; ECL Western Blotting Substrate) and quantitated using GeneSnap and GeneTools (Syngene).

Statistical analyses

To compare epidermal thickness (μm), LI (% BrdU-positive cells), and immune cell infiltration (number of positive cells per field), data were presented as the mean \pm SEM. For comparisons of epidermal thickness, LI, and immune cell infiltration, the Mann-Whitney *U* test was used ($P \leq 0.05$). For comparison of tumor incidence, the χ^2 test was used ($P \leq 0.05$). For comparison of tumor multiplicity data, the Mann-Whitney *U* test was again used ($P \leq 0.05$).

Results

Effect of rapamycin on skin tumor promotion

Two-stage skin carcinogenesis experiments were carried out in wild-type mice to evaluate the effect of rapamycin on skin tumor promotion by TPA. Groups of female FVB/N mice 7 to 8 weeks of age were initiated with 25 nmol of DMBA, and then 2 weeks later, treated topically with various doses of rapamycin (5–200 nmol) or acetone vehicle followed 30 minutes later by 6.8 nmol of TPA. All treatments were given twice weekly for the duration of the experiment (25 weeks). Tumor incidence (percentage of mice with papillomas) and tumor multiplicity (average number of papillomas per mouse) were measured weekly

for each group. As shown in Figure 1A, rapamycin exerted a powerful antipromoting effect. Treatment groups receiving topical application of 200, 100, or 50 nmol of rapamycin 30 minutes prior to application of TPA had complete inhibition of papilloma development (Fig. 1A). In addition, there was also a significant reduction in papilloma development in the groups receiving 20 and 5 nmol doses of rapamycin compared with the DMBA-TPA only control group. In this regard, at week 25, a 92% inhibition of papilloma development was observed in the group receiving 20 nmol of rapamycin prior to TPA, and a 49% inhibition of papilloma development was observed in the group receiving 5 nmol of rapamycin prior to TPA ($P < 0.05$; Mann-Whitney *U* test; see again Fig. 1A). No papillomas developed in the groups initiated with DMBA followed by twice weekly treatments with either acetone or 200 nmol of rapamycin. In addition, we did not observe a significant number of SCCs in any of the groups at the end of the tumor experiment, consistent with previous studies from our laboratory that used an even higher initiating dose of DMBA (26). These studies showed that most SCCs developed in FVB/N mice after 25 weeks of promotion.

Tumor latency was also affected in groups treated with 20 and 5 nmol of rapamycin prior to treatment with TPA. The time to 50% incidence of papillomas in the TPA promotion control group was 10 to 11 weeks versus 16 to 17 weeks in the 5 nmol rapamycin-treated group (Fig. 1B). Mice in the 20 nmol rapamycin-pretreated group reached only 32% tumor incidence as determined at week 25 (Fig. 1B). Differences in tumor latency were statistically significant ($P < 0.05$; χ^2 test). These data clearly show that rapamycin was a potent inhibitor of TPA skin tumor promotion, dramatically reducing both tumor multiplicity and tumor incidence and altering latency in a dose-dependent manner. Note that a repeat experiment was conducted using similar doses of rapamycin for a duration of 23 weeks of promotion with TPA. The results were very similar to those shown in Figure 1A and B confirming the potent inhibitory effect of rapamycin on TPA promotion. In this repeat experiment, the time to 50% incidence of papillomas was 10 to 11 weeks in the TPA promotion control group versus 15 to 16 weeks in the 5 nmol rapamycin-treated group. In addition, at 23 weeks of promotion, the 5 nmol rapamycin-treated group had an 85% inhibition of papilloma development compared with the TPA control group (1.44 ± 0.4 vs. 9.75 ± 0.5 , respectively; $P < 0.05$). Furthermore, topical treatment with rapamycin had no effect on body weight gain in any of the experimental groups over the course of these experiments (data not shown).

On the basis of the data in Figure 1A and B showing that rapamycin dramatically inhibited the promotion of skin tumors, an experiment was conducted to determine whether topical treatments of rapamycin would inhibit growth of existing papillomas generated by the two-stage protocol. For this experiment, female FVB/N mice 7 to 8 weeks of age were initiated with 25 nmol of DMBA and promotion was begun 2 weeks later with 6.8 nmol of TPA. Promotion was continued twice weekly for 15 weeks. At




Figure 1. Effect of rapamycin treatment on skin tumor promotion by TPA. Groups of 20 female FVB/N mice, 7 to 8 weeks of age, were initiated with 25 nmol of DMBA. Two weeks following initiation, mice were treated topically twice weekly with various rapamycin (rapa) doses or acetone, followed by promotion with 6.8 nmol TPA for 25 weeks. A, tumor multiplicity (average papillomas per mouse \pm SEM). Differences in the average number of papillomas per mouse at 25 weeks between 20 nmol (●) and 5 nmol (▲) rapamycin + TPA treated groups and the corresponding 6.8 nmol (■) TPA-treated group were statistically significant (*, $P < 0.05$; ***, $P < 0.001$, respectively; Mann-Whitney U test). B, tumor incidence (percentage of mice with papillomas). Differences in tumor incidence at 25 weeks between the 20 nmol (●) rapamycin + TPA group and the 6.8 nmol TPA (■) group were statistically significant (**, $P < 0.01$; χ^2 test). C, female FVB mice, 7 to 8 weeks of age, were initiated with 25 nmol of DMBA and 2 weeks following initiation, promotion began with 6.8 nmol of TPA. Promotion was continued twice a week for 15 weeks. At 15 weeks, mice were randomized and received either 100 or 20 nmol of rapamycin or acetone either alone or followed by treatment with 6.8 nmol TPA.

week 15, mice were randomized into groups that received topical applications of 100 or 20 nmol of rapamycin alone, acetone alone, or rapamycin treatments (100 and 20 nmol) 30 minutes prior to continued promotion with 6.8 nmol of TPA. All treatments continued until week 25. Tumor multiplicity and tumor incidence were determined each week. As shown in Figure 1C, topical treatment of rapamycin induced regression or inhibited growth of existing skin tumors. All groups receiving acetone or a dose of rapamycin with or without continued promotion with 6.8 nmol of TPA had statistically significant reductions in tumor multiplicity compared with the group that continued with just 6.8 nmol TPA treatments alone ($P < 0.05$; Mann-Whitney U test). At week 25, there was a 48% reduction of papilloma development in the acetone-treated group compared with the 6.8 nmol-treated group (Fig. 1C). There was a 74% inhibition in the group receiving 100 nmol of rapamycin alone and a 67% inhibition in the group receiving 100 nmol of rapamycin prior to 6.8 nmol of TPA (Fig. 1C). There was a 75% inhibition of papillomas in the group receiving 20 nmol of rapamycin alone and a 49% inhibition in the mice receiving 20 nmol of rapamycin prior to treatment with 6.8 nmol of TPA (Fig. 1C). There were no statistically significant differences in tumor incidence (data not shown). These data indicate that, in addition to dramatically preventing the formation of skin tumors, topically applied rapamycin inhibited growth and/or induced regression of existing papillomas even in the presence of continued TPA treatment.

Effect of rapamycin on TPA-induced epidermal hyperproliferation

Because of the dramatic effect of rapamycin on skin tumor promotion by TPA, the possible effects of rapamycin on TPA-induced epidermal hyperproliferation were examined. For these experiments, groups of female FVB/N mice, 7 to 8 weeks of age, were treated topically with acetone (vehicle) or various doses of rapamycin (5–200 nmol) followed 30 minutes later by 6.8 nmol of TPA. This treatment regimen was continued twice weekly for 2 weeks (i.e., 4 treatments total), and mice were sacrificed 48 hours after the final treatment. After sacrifice, the skin was removed and processed for histologic examination. Whole skin sections were evaluated for epidermal hyperplasia (as measured by epidermal thickness) and epidermal LI (as measured by BrdU incorporation). Figure 2A shows representative H&E- and BrdU-stained sections of dorsal skin after multiple treatments with either acetone, 6.8 nmol TPA, or 200 nmol of rapamycin followed by 6.8 nmol of TPA. Visual inspection of the sections revealed that rapamycin significantly reduced epidermal hyperplasia as well

Differences in tumor multiplicity (average papillomas per mouse \pm SEM) were statistically significant between the rapamycin-treated groups and the 6.8 nmol TPA-treated group. Acetone (●) and 20 nmol rapamycin + TPA (◆) groups (*, $P < 0.05$), 100 nmol rapamycin + TPA (×; **, $P < 0.01$), 20 nmol rapamycin (■), and 100 nmol rapamycin (–; ***, $P < 0.0001$); Mann-Whitney U test.




Figure 2. Effect of rapamycin treatment on TPA-induced epidermal hyperproliferation. A, representative sections of H&E and BrdU stains of dorsal skin collected from female FVB mice after multiple treatments with either acetone, 6.8 nmol TPA, or 200 nmol rapamycin (rapa) followed by 6.8 nmol TPA (twice a week for 2 weeks). B, quantitative evaluation of the effects of rapamycin on TPA-induced epidermal hyperplasia (epidermal thickness). C, quantitative evaluation of the effects of rapamycin on TPA-induced epidermal hyperproliferation (labeling index:LI). Values represent the mean \pm SEM. (*, $P < 0.05$; Mann-Whitney U test).

as LI when applied 30 minutes prior to TPA application. Quantitative analyses of the effect of rapamycin on TPA-induced epidermal hyperplasia and LI are summarized in Figure 2B and C, respectively. All doses of rapamycin used (200, 100, 50, 20, and 5 nmol) produced statistically significant reductions in epidermal thickness and LI induced by TPA treatment ($P < 0.05$; Mann-Whitney U test). These data show that rapamycin effectively blocked TPA-induced epidermal hyperproliferation and that this effect may explain its ability, at least in part, to inhibit skin tumor promotion by TPA.

Effect of rapamycin on dermal inflammatory cell infiltration

During the course of analyzing skin sections from rapamycin-treated mice, a significant decrease in dermal inflammation and dermal inflammatory cell numbers was observed. Therefore, the effect of topical treatments of rapamycin prior to TPA on dermal inflammatory cell infiltration was further examined. For these experiments,

groups of female FVB/N mice, 7 to 8 weeks of age, were treated topically with acetone (vehicle) or various doses of rapamycin (5–200 nmol) followed 30 minutes later by 6.8 nmol of TPA. This treatment regimen was continued twice weekly for 2 weeks, and mice were sacrificed 48 hours after the final treatment for histochemical and immunohistochemical analysis of various inflammatory cells. Whole skin sections were processed and stained for the following markers including CD3 (T cells), S100A9 (macrophages), LY6G (neutrophils), and toluidine blue (mast cells). As noted above, visual inspection of skin sections revealed that rapamycin dramatically reduced infiltration of all 4 types of inflammatory cells as seen in Figure 3 for the 200-nmol dose of rapamycin (A–D, respectively). Quantitative analyses of each cell type at 2 different doses of rapamycin (200 and 5 nmol) are shown in Figure 4. Rapamycin at both doses presented produced statistically significant reductions in the number of all inflammatory cell types examined ($P < 0.05$; Mann-Whitney U test).




Figure 3. Effect of rapamycin treatment on TPA-induced dermal inflammation. **A**, representative sections of CD3-stained (T cells) dorsal skin sections collected after multiple treatments of acetone, 6.8 nmol of TPA, or 200 nmol rapamycin (rapa) + TPA. **B**, representative sections of S100A9-stained (macrophages) dorsal skin sections collected after multiple treatments with either acetone, 6.8 nmol of TPA, or 200 nmol rapamycin + TPA. **C**, representative sections of LY6G-stained (neutrophils) dorsal skin sections collected after multiple treatments with either acetone, 6.8 nmol of TPA, or 200 nmol rapamycin + TPA. **D**, representative sections of toluidine blue-stained (mast cells) dorsal skin sections collected after multiple treatments with either acetone, 6.8 nmol of TPA, or 200 nmol rapamycin + TPA. Arrows point to the indicated inflammatory cells in each panel.

Effect of rapamycin on mTOR signaling in epidermis

To further explore the potential mechanisms by which rapamycin inhibited TPA-induced epidermal hyperproliferation and skin tumor promotion, experiments were conducted to evaluate changes in epidermal Akt and mTOR signaling pathways. For these experiments, female FVB/N mice, 7 to 8 weeks of age, were treated topically with either acetone or various doses of rapamycin (5–1,000 nmol) 30 minutes prior to treatment with 6.8 nmol of TPA twice weekly for 2 weeks (total of 4 treatments). Note that a higher dose of rapamycin (1,000 nmol) was used in initial Western blot experiments (Fig. 5A). However, in subsequent experiments, it was not used, as doses of 50, 100, and 200 nmol rapamycin completely inhibited skin tumor promotion by TPA. Mice were sacrificed 6 hours after final treatment and epidermal protein lysates were prepared for Western blot analyses of Akt, mTOR, and several mTORC1 downstream effector molecules. Topical application of TPA using this protocol led to phosphorylation of mTOR (Ser²⁴⁴⁸), and downstream effectors of mTORC1 including p70S6K (Thr³⁸⁹), p4E-BP1 (Thr^{37/46} and Ser⁶⁵), and pS6 ribosomal (Ser^{240/244}); (Fig. 5A and B) as well as phosphorylation of Akt (Thr³⁰⁸ and Ser⁴⁷³; Fig. 5C and D) as expected on the basis of previous studies (23, 24). Although the phosphorylation of mTOR (Ser²⁴⁴⁸) was reduced somewhat at several doses of rapamycin, the most dramatic effects were seen on phosphorylation of p70S6K and S6 ribosomal protein (Fig. 5A and B). In this regard,

phosphorylation of the mTORC1 downstream effectors p70S6K (Thr³⁸⁹) and p-S6 ribosomal protein (Ser^{240/244}) was decreased in the rapamycin-treated groups in a dose-dependent manner. In addition, at the 1,000-nmol dose, p4E-BP1 (Thr^{37/46} and Ser⁶⁵) was decreased as compared with the TPA-treated group. Rapamycin given at a dose of 200 nmol in this multiple treatment regimen appeared to increase Akt phosphorylation at Ser⁴⁷³ as well as increase phosphorylation at the Thr³⁰⁸ site (again see Fig. 5C and D). None of the other doses of rapamycin appeared to affect Akt phosphorylation at either site. Figure 5B and D show the quantitation of the Western blot analyses shown in Figure 5A and C, respectively. Similar results were obtained in a separate, independent experiment. The Western blot analyses shown in Figure 5A and C are representative of both experiments. The quantitation shown in Figure 5B and D represent an average from both of these experiments. Collectively, these data suggest that treatment with rapamycin led to inhibition of TPA-induced mTORC1 downstream signaling, particularly through the p70S6K and S6 ribosomal protein pathway. Furthermore, at higher doses (≥ 200 nmol per mouse), rapamycin also appeared to increase Akt phosphorylation at Thr³⁰⁸.

Discussion

The current study was designed to examine the effects of rapamycin, an established mTORC1 inhibitor on tumor




Figure 4. Quantitative analysis of effect of rapamycin on TPA-induced dermal inflammation. A, average number of positive cells per 24 fields ($200 \mu\text{m}^2$) for CD3-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol rapamycin + TPA groups treated skins. B, average number of positive cells per 24 fields ($200 \mu\text{m}^2$) for S100A9-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol rapamycin + TPA groups treated skins. C, average number of positive cells per 24 fields ($200 \mu\text{m}^2$) for LY6G-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol rapamycin + TPA groups treated skins. D, average number of positive cells per 24 fields ($200 \mu\text{m}^2$) for toluidine blue-stained sections in acetone, 6.8 nmol TPA, 200 nmol rapamycin + TPA, and 5 nmol rapamycin + TPA groups treated skins. Values represent the mean \pm SEM. (*, $P < 0.05$; Mann-Whitney U test).

promotion during two-stage carcinogenesis in mouse skin. In addition, the effects of rapamycin on TPA-induced mTOR signaling pathways in epidermis as well as TPA-induced epidermal hyperplasia and proliferation were examined. Following topical application of diverse tumor promoters, including TPA, multiple growth factor signaling pathways are activated (27). The PI3K/Akt pathway is activated with subsequent phosphorylation of downstream targets mTOR, GSK3 β , and Bad (23, 24). Targeting one or more of these pathways may be an effective way to inhibit tumor promotion. The current results show that topical treatment of mouse skin with rapamycin prior to TPA dramatically inhibited tumor promotion in a dose-dependent manner. In this regard, significant decreases in both tumor multiplicity and tumor incidence were observed (Fig. 1A and B). Topical application of rapamycin to existing skin papillomas also induced regression and/or inhibited their growth (Fig. 1C). Mechanistic studies revealed that rapamycin inhibited TPA-induced epidermal hyper-

plasia and hyperproliferation (Fig. 2). In addition, rapamycin inhibited TPA-induced dermal inflammation as assessed by its effects on infiltration of several types of inflammatory cells. Finally, rapamycin effectively inhibited TPA-induced activation of mTORC1 signaling at doses that inhibited skin tumor promotion. Collectively, the data show that rapamycin is an extremely potent inhibitor of skin tumor promotion by TPA.

Recently, several laboratories including our own have shown a critical role for Akt signaling in mouse skin carcinogenesis and tumor promotion. In this regard, overexpression of insulin-like growth factor 1 (IGF-1) in the epidermis of transgenic mice induced epidermal hyperplasia, enhanced susceptibility to two-stage skin carcinogenesis, and led to spontaneous skin tumor formation (25, 28). Biochemical alterations in the epidermis of these transgenic mice included elevated levels of PI3K and Akt activity and elevated phospho-mTOR and cell-cycle regulatory proteins (28, 29). Topical application of LY294002, a PI3K-specific




Figure 5. Effect of rapamycin on TPA-induced mTOR signaling in mouse epidermis using a multiple treatment protocol. Pooled protein lysates were prepared from the epidermal scrapings of FVB/N mice undergoing a multiple treatment regimen of acetone, 6.8 nmol TPA, 200 and 1000 nmol rapamycin (rapa), or various doses of rapamycin (5–1,000 nmol) prior to 6.8 nmol TPA. Western blot analyses were then conducted to examine activation of Akt and mTOR and downstream targets. A, Western blot analysis of mTOR and downstream signaling molecules. B, quantification of Western blot analyses in A. C, Western blot analysis of Akt phosphorylation status. D, quantification of Western blot analysis in C. These experiments were repeated with nearly identical results. Note that the quantitations shown in B and D represent an average of the two experiments, whereas the Western blot analysis in A and C are from a single representative experiment.

inhibitor, not only directly inhibited these constitutive epidermal biochemical changes but also inhibited IGF-I-mediated skin tumor promotion in a dose-dependent manner (29). Segrelles and colleagues (22) reported sustained activation of epidermal Akt throughout two-stage carcinogenesis in mouse skin. More recent data published by this same group (30) and others (31, 32) have further confirmed the involvement of Akt-mediated cellular proliferation in mouse skin tumorigenesis. Transgenic mice overexpressing either Akt^{wt} or Akt^{myr} in the epidermis exhibited significantly enhanced susceptibility to two-stage skin carcinogenesis (24). Collectively, the data from two-stage carcinogenesis experiments using both IGF-I and Akt transgenic mice further support the hypothesis that elevated Akt signaling can lead to increased susceptibility to epithelial carcinogenesis. The underlying mechanisms involved in Akt-mediated spontaneous tumorigenesis and the enhanced susceptibility to chemically induced carcinogenesis in mouse skin remain to be fully established, although studies conducted in BK5.Akt^{wt} and BK5.Akt^{myr} mice identified potential molecular targets through which Akt exerts its effects on tumorigenesis. In this regard, overexpression or constitutive activation of Akt led to enhanced epidermal proliferation that correlated with significant elevations of G₁ to S-phase cell-cycle proteins including cyclin D1 (24). In conjunction with these changes, a marked increase in signaling downstream of mTORC1 was observed suggesting

that protein translation was also upregulated. As noted above, topical application of TPA leads to activation of Akt and mTORC1 signaling (23, 24). Furthermore, both IGF-I and Akt transgenic mice were highly susceptible to TPA-induced epidermal hyperproliferation compared with wild-type mice. In addition, heightened mTORC1 activation is seen in these mice following TPA treatment. Overall, these data support the hypothesis that mTORC1 signaling may represent one of the important Akt downstream targets during skin tumor promotion. Recently, Lu and colleagues (33) reported that overexpression of Rheb (an activator of mTORC1) in epidermis led to spontaneous skin tumor development and increased sensitivity to DMBA-induced tumorigenesis lending further support to this hypothesis.

As noted in the Introduction, several recent studies have reported that rapamycin effectively inhibited either development of tumors and/or inhibited growth of existing tumors in mouse models (12–21). In the mouse skin model, rapamycin (given intraperitoneally) was shown to reduce the number of both early tumors and late tumors in protocols where tumors were already present on the backs of the mice at the time of treatment (16). In this particular study, the antitumor effect of rapamycin was attributed to its ability to induce apoptosis in tumor cells through reduced signaling downstream of mTORC1 (as assessed by levels of pS6) and reduced levels of the cell-cycle proteins proliferating cell nuclear antigen (PCNA)

and cyclin D1. In studies related to UV skin carcinogenesis, de Gruijl and colleagues (15) reported that rapamycin (given in the diet) delayed the appearance and reduced the multiplicity of larger tumors (>4 mm). Our current data show that rapamycin was a remarkably potent inhibitor of skin tumor promotion by TPA and that this effect was related to inhibition of mTORC1 signaling in keratinocytes and inhibition of TPA-induced epidermal hyperproliferation. In addition, rapamycin treatment led to a significant reduction in dermal inflammation, which may have also contributed to its potent inhibitory effect.

As shown in Figure 5, topical treatment with rapamycin given 30 minutes prior to application of TPA inhibited TPA-induced epidermal mTORC1 signaling as assessed by decreased phosphorylation of mTOR (Ser²⁴⁴⁸) and the mTORC1 downstream targets p70S6K (Thr³⁸⁹) and pS6 ribosomal protein (Ser^{240/244}). Rapamycin appeared to have less of an effect on 4E-BP1 phosphorylation with a reduction seen only at the highest dose of rapamycin tested (1,000 nmol). This observation of lower inhibition of 4E-BP1 phosphorylation by rapamycin is consistent with previously published data showing that rapamycin only partially inhibited phosphorylation of 4E-BP1 but fully inhibited phosphorylation of p70S6K (34, 35). Furthermore, Gingras and colleagues (36) reported that phosphorylation at the Thr³⁷ and Thr⁴⁶ sites of 4E-BP1 by mTOR did not abolish its binding with eIF4E and that subsequent phosphorylation by other kinases is needed to release 4E-BP1 from eIF4E for translational activation. Thus, the phosphorylation of 4E-BP1 and subsequent requirements for release from eIF4E are complex. Our current data suggest that the effects of rapamycin on this mTORC1 signaling pathway may be less important than its effects on the p70S6K and S6 ribosomal downstream pathway in terms of inhibition of skin tumor promotion. It is interesting to note that rapamycin given at a dose of 200 nmol caused an increase in Akt phosphorylation at Thr³⁰⁸, which was not apparent at the lower doses (100, 50, 20, and 5 nmol). Previous studies have shown an increase in Akt activity upon treatment with mTOR inhibitors due to a reduction of mTORC1 feedback inhibition of the PI3K/Akt pathway (37, 38). The increase in Akt phosphorylation at Thr³⁰⁸ seen with rapamycin treatment at the 200 nmol dose in the multiple treatment regimen may have been due to a similar inhibition of the mTORC1-dependent negative feedback loop. In contrast, phosphorylation of Akt at Ser⁴⁷³ was not decreased with the highest dose of rapamycin used (again 200 nmol per mouse; Fig. 5) and may have been slightly increased. However, in preliminary experiments, we have observed a decreased phosphorylation of PRAS40 (Thr²⁴⁶), at the Akt-specific phosphorylation site (data not shown). Sarbassov and colleagues (39) recently reported that prolonged treatment with rapamycin inhibited mTORC2 assembly and Akt activity *in vitro*. Further work will be necessary to determine whether a multiple treatment regimen of higher doses of rapamycin (i.e., ≥ 200 nmol) prior to TPA affected the mTORC2 complex. Nevertheless, lower doses of rapamycin (i.e., 100, 50, 20, and 5 nmol) effectively inhibited TPA promotion of skin tumors and

epidermal mTORC1 signaling without affecting phosphorylation of Akt at either site. Thus, inhibition of mTORC1 signaling appeared to be the main biochemical change associated with inhibition of skin tumor promotion at these lower doses of rapamycin.

Immunohistochemical analyses of the rapamycin-treated skins revealed a significant decrease in the number of T cells (Figs. 3A and 4A) and macrophages (Figs. 3B and 4B) present in the dermis. In addition, a significant reduction in neutrophils (Figs. 3C and 4C) and mast cells (Figs. 3D and 4D) was also observed. Granville and colleagues (17) reported no significant decreases in macrophage content of tumors from rapamycin-treated mice compared with the tumors from the control (vehicle treated) mice. In addition, Amornphimoltham and colleagues also reported no differences in macrophage or T-cell content of skin tumors after rapamycin treatment (16). However, the experimental protocols used in these studies differed from that used in the current study. In this regard, the route of exposure to rapamycin was different in both of these previously published studies (intraperitoneal injection). In addition, both of these previously published studies evaluated inflammation following rapamycin treatment in pre-existing tumors. Overall, the current data suggest that rapamycin may exert anti-inflammatory effects earlier in the carcinogenesis process, especially during the early stage of tumor promotion and that this may have also contributed to its potent antitumor promoting activity.

In conclusion, rapamycin was a remarkably effective inhibitor of skin tumor promotion by TPA. On a molar basis, rapamycin is one of the most potent inhibitors of phorbol ester skin tumor promotion discovered to date. The ability of rapamycin to inhibit skin tumor promotion by TPA was associated with the inhibition of mTORC1 signaling in keratinocytes and inhibition of TPA-induced epidermal hyperproliferation. In addition, topical treatment with rapamycin significantly inhibited TPA-induced inflammation as assessed by a significant reduction in infiltrating T cells, macrophages, neutrophils and mast cells. Together, the current data support the hypothesis that elevated mTORC1 and activation of downstream signaling pathways is an important event during tumor promotion. In addition, the data support the importance of mTORC1 as a potential target for prevention of epithelial cancers. Targeting this pathway either alone or in combination with other agents may be an effective strategy for the prevention of epithelial cancers.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by NIH grants CA037111 and CA129409. T. Moore was supported by NIEHS training grant ES007247.

Received December 13, 2010; revised January 28, 2011; accepted February 21, 2011; published online July 6, 2011.

References

- Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell* 2003;4:257–62.
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006;441:424–30.
- Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. *Mol Cancer Ther* 2007;6:2139–48.
- Hay N. The Akt-mTOR tango and its relevance to cancer. *Cancer Cell* 2005;8:179–83.
- Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell* 2007;12:9–22.
- Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. *Oncogene* 2006;25:6416–22.
- Huang JX, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. *Biochem Soc Trans* 2009;37:217–22.
- Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007;129:1261–74.
- Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. *Cell* 2006;127:125–37.
- Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. *Mol Cancer Ther* 2008;7:1347–54.
- Kopelovich L, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. *Cancer Epidemiol Biomarkers Prev* 2007;16:1330–40.
- Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Res* 2005;65:9953–61.
- Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. *Clin Cancer Res* 2008;14:5124–30.
- Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma *in situ*. *Clin Cancer Res* 2006;12:2613–21.
- de Grujil FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. *Int J Cancer* 2010;127:796–804.
- Amornphimoltham P, Leelahavanichkul K, Molinolo A, Patel V, Gutkind JS. Inhibition of mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. *Clin Cancer Res* 2008;14:8094–101.
- Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. *Clin Cancer Res* 2007;13:2281–9.
- Yan Y, Wang Y, Tan Q, Haray Y, Yun TK, Lubet RA, et al. Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. *Neoplasia* 2006;8:52–8.
- Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. *Cancer Res* 2009;69:4159–66.
- Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. *Cancer Res* 2005;65:5325–36.
- Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, et al. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. *Am J Pathol* 2009;174:1869–79.
- Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. *Oncogene* 2002;21:53–64.
- Lu J, Rho O, Wilker E, Beltran L, Digiovanni J. Activation of epidermal akt by diverse mouse skin tumor promoters. *Mol Cancer Res* 2007;5:1342–52.
- Segrelles C, Lu J, Hammann B, Santos M, Moral M, Cascallana JL, et al. Deregulated activity of akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. *Cancer Res* 2007;67:10879–88.
- Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. *Oncogene* 1997;14:1725–34.
- Matsumoto T, Jiang J, Kiguchi K, Ruffino L, Carbajal S, Beltran L, et al. Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. *Cancer Res* 2003;63:4819–28.
- Rho O, Kim DJ, Kiguchi K, Digiovanni J. Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. *Mol Carcinog* 2011;50:264–9.
- DiGiovanni J, Bol DK, Wilker E, Beltran L, Carbajal S, Moats S, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. *Cancer Res* 2000;60:1561–70.
- Wilker E, Lu J, Rho O, Carbajal S, Beltran L, DiGiovanni J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. *Mol Carcinog* 2005;44:137–45.
- Segrelles C, Moral M, Lara MF, Ruiz S, Santos M, Leis H, et al. Molecular determinants of Akt-induced keratinocyte transformation. *Oncogene* 2006;25:1174–85.
- Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR, et al. Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. *Anticancer Res* 2004;24:2773–81.
- Affara NI, Trempus CS, Schanbacher BL, Pei P, Mallery SR, Bauer JA, et al. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. *Anticancer Res* 2006;26:2805–20.
- Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, et al. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. *Cancer Res* 2010;70:3287–98.
- Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggiero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. *PLoS Biol* 2009;7:e38.
- McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC Jr. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. *Mol Cell Biol* 2002;22:7428–38.
- Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes Dev* 1999;13:1422–37.
- O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res* 2006;66:1500–8.
- Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. *Mol Cell* 2006;24:185–97.
- Sarbasov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* 2006;22:159–68.

Cancer Prevention Research

Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate

L. Allyson Checkley, Okkyung Rho, Tricia Moore, et al.

Cancer Prev Res 2011;4:1011-1020.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/4/7/1011>

Supplementary Material Access the most recent supplemental material at:
<http://cancerpreventionresearch.aacrjournals.org/content/suppl/2011/06/28/4.7.1011.DC1>
<http://cancerpreventionresearch.aacrjournals.org/content/suppl/2011/06/28/4.7.1011.DC2>

Cited articles This article cites 39 articles, 20 of which you can access for free at:
<http://cancerpreventionresearch.aacrjournals.org/content/4/7/1011.full#ref-list-1>

Citing articles This article has been cited by 13 HighWire-hosted articles. Access the articles at:
<http://cancerpreventionresearch.aacrjournals.org/content/4/7/1011.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerpreventionresearch.aacrjournals.org/content/4/7/1011>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.